Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study

Annunziata Lapolla, Cesare Berra, Massimo Boemi, Antonio Carlo Bossi, Riccardo Candido, Graziano Di Cianni, Simona Frontoni, Stefano Genovese, Paola Ponzani, Vincenzo Provenzano, Giuseppina T Russo, Luigi Sciangula, Natalino Simioni, Cristiano Bette, Antonio Nicolucci, NN2211-4118 Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice.

METHODS: ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011.

RESULTS: A total of 1723 patients were included in the analysis. At baseline, mean age was 58.9 years, duration of diabetes was 9.6 years, and HbA1c was 8.3%. At 12 months, 36.1% of patients were prescribed the maximum 1.8 mg dose; 43.5% [95% confidence interval (CI): 40.9; 46.2] of patients attained the primary outcome of a reduction in HbA1c of ≥ 1% point at 12 months. At 24 months, 40.9% (95% CI 38.1; 43.7) of patients had attained the HbA1c target of ≤ 7%. Additionally, body weight significantly decreased by 3.4 kg (95% CI - 3.6; - 3.1, p < 0.0001).

CONCLUSION: In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. The data support the use of liraglutide as an effective treatment for T2D in clinical practice.

FUNDING: Novo Nordisk S.p.A.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02255266.

Original languageEnglish
Pages (from-to)243-253
Number of pages11
JournalAdvances in Therapy
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2018

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study'. Together they form a unique fingerprint.

Cite this